The Trump administration struck agreements with Novo Nordisk and Eli Lilly to lower prices and expand access to leading obesity drugs and announced plans for a government drug portal. In parallel, the FDA issued a second round of Commissioner’s National Priority Vouchers (CNPVs) tied to those deals, giving select drug candidates a dramatically accelerated review window. The move pairs pricing concessions from manufacturers with regulatory speed-ups; the program and administration involvement prompted immediate industry scrutiny about precedent and implementation.